Overview: “CJC-1295 no DAC” is used inconsistently. Learn how it differs from long-acting CJC-1295, what combination evidence exists and what remains unknown.
On this page
“CJC-1295 no DAC” is a market label, not a clean match for the published CJC-1295 evidence.
The phrase is commonly used for a short-acting growth-hormone-releasing hormone analogue, often called modified GRF(1-29). Published CJC-1295 studies, however, largely concern the long-acting Drug Affinity Complex form. Treating the names as interchangeable can misrepresent both exposure and evidence.
What does “no DAC” mean?
| Term | What it usually refers to | Evidence caution |
|---|---|---|
| CJC-1295 with DAC | A long-acting GHRH analogue designed to bind serum albumin | This is the form studied in the best-known healthy-adult CJC-1295 trials |
| “CJC-1295 no DAC” | A commercial label often used for modified GRF(1-29) | The label is inconsistent and should not inherit the long-acting molecule’s results |
| Ipamorelin | A growth-hormone secretagogue acting at the ghrelin receptor | Human studies show acute pharmacology, not the broad wellness outcomes promoted online |
The DAC in CJC-1295 is a reactive group that extends exposure through albumin binding. Removing that feature changes the pharmacological proposition. It does not simply create an otherwise identical, shorter version with an automatically transferable evidence base.
What human evidence actually exists?
| Question | What the research shows | What it does not show |
|---|---|---|
| Can long-acting CJC-1295 raise GH and IGF-1? | Small controlled studies in healthy adults found dose-related increases in growth hormone and IGF-1. | They did not establish lasting improvements in strength, body composition, recovery, sleep or lifespan. |
| Can ipamorelin trigger GH release? | Early human pharmacology work showed an acute growth-hormone response. | An acute hormone response is not a patient-important benefit. |
| Has the “no DAC” plus ipamorelin combination been validated? | No persuasive peer-reviewed clinical trial was identified for the popular combination and claimed uses. | Separate studies of related agents cannot prove combination efficacy or safety. |
For the underlying trials and regulator records, see our CJC-1295 and ipamorelin evidence guide. The separate CJC-1295 with DAC profile explains the long-acting molecule studied in humans.
Why combination claims are a larger leap
CJC-related compounds and ipamorelin act through different receptors in the same hormone axis. That mechanistic complementarity is a hypothesis, not proof of improved health outcomes. A reliable combination claim would require a defined formulation, randomized comparison, clinically meaningful outcomes, adequate follow-up and systematic safety reporting. Those elements are missing.
| Common claim | Evidence grade | Reason |
|---|---|---|
| “Synergistic” growth-hormone release | Mechanistic hypothesis | Different receptor pathways make the idea biologically plausible, but the marketed combination lacks decisive clinical testing |
| Fat loss or muscle gain | Unproven | No robust trial demonstrates these outcomes for the combination |
| Better sleep or recovery | Unproven | Online testimony is not a controlled clinical endpoint |
| Long-term safety | Unknown | Short biomarker studies cannot resolve uncommon or delayed harm |
Australian and sport context
Growth-hormone-releasing factors and secretagogues are prescription-only substances under the current Australian Poisons Standard, with named entries in Appendix D. Scheduling does not mean a product is approved on the Australian Register of Therapeutic Goods. The TGA warns that products promoted online as “research-grade” or compounded peptides may be unapproved and may present quality, legality and advertising issues.
The 2026 World Anti-Doping Agency Prohibited List names CJC-1295 and ipamorelin in growth-hormone-related categories. Athletes should treat the combination as prohibited and use official anti-doping medicine-checking channels for any therapeutic question.
Questions readers ask
Is “CJC-1295 no DAC” the same molecule used in the major CJC-1295 trials?
No. The best-known CJC-1295 trials used a long-acting Drug Affinity Complex form. “No DAC” is commonly used for modified GRF(1-29), and commercial naming is inconsistent.
Does a rise in GH or IGF-1 prove fat loss or recovery?
No. Biomarker movement can establish biological activity, but it does not establish a clinically meaningful benefit.
Has the combination been studied in a strong randomized trial?
We did not identify a persuasive peer-reviewed randomized trial of the marketed “no DAC” plus ipamorelin combination for body composition, recovery, sleep or longevity.
Is it approved in Australia?
Australian scheduling and ARTG approval are different. A Schedule 4 entry does not establish that a particular product or claimed use is TGA-approved.
Is it prohibited in sport?
The 2026 WADA Prohibited List names both CJC-1295 and ipamorelin. Athletes should consult official anti-doping resources rather than seller descriptions.
Primary sources
- Teichman et al. — prolonged stimulation of GH and IGF-1 after CJC-1295 in healthy adults
- Ionescu and Frohman — CJC-1295 effects on GH pulsatility
- Raun et al. — human pharmacokinetics and pharmacodynamics of ipamorelin
- TGA — public health risks of unapproved peptides
- WADA — 2026 Prohibited List
Scope: Evidence and regulatory information only. This page does not provide dosing, administration, sourcing or personal medical advice. No independent clinician reviewer is attributed to this update.
How to cite this research profile
CJC-1295 No DAC + Ipamorelin: Terminology, Evidence and Safety Gaps. Elite Peps Australia. Published 30 June 2026; updated 30 September 2026. https://elitepepsaustralia.com/product/cjc-1295-no-dac-ipamorelin/
Verification: Follow the linked primary studies, trial records and regulator documents in the references above. Regulatory status is date-sensitive.